Qiagen NV
NYSE:QGEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (14.1), the stock would be worth $45.42 (18% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 11.9 | $38.41 |
0%
|
| 3-Year Average | 14.1 | $45.42 |
+18%
|
| 5-Year Average | 14 | $45.14 |
+18%
|
| Industry Average | 13.7 | $44.12 |
+15%
|
| Country Average | 12.4 | $39.95 |
+4%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
$9.4B
|
/ |
Jan 2026
$745.2m
|
= |
|
|
$9.4B
|
/ |
Dec 2026
$836.4m
|
= |
|
|
$9.4B
|
/ |
Dec 2027
$905.6m
|
= |
|
|
$9.4B
|
/ |
Dec 2028
$978.4m
|
= |
|
|
$9.4B
|
/ |
Dec 2029
$1B
|
= |
|
|
$9.4B
|
/ |
Dec 2030
$1.1B
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| NL |
|
Qiagen NV
NYSE:QGEN
|
8.3B USD | 11.9 | 19.6 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 1 226.4 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
176.7B USD | 18.4 | 26.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
125.4B USD | 17.6 | 34 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 30.1 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 16.3 | 15.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 16.1 | -118.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 18.6 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.4B USD | 30.5 | 47.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.5B USD | 11.5 | 20.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD | 22.3 | 30 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.9 |
| Median | 12.4 |
| 70th Percentile | 19.3 |
| Max | 706 |
Other Multiples
Qiagen NV
Glance View
Qiagen NV, a luminary in the realm of biotechnology, navigates the intricate world of molecular diagnostics and testing with a blend of innovation and expertise. Originating in 1984 in the Netherlands, this company has grown into a formidable presence in the life sciences sector. Qiagen's journey revolves around its core mission: to enable advancements in science and healthcare by providing technologies and solutions that unlock molecular insights. At the heart of its operations lies a comprehensive portfolio of sample and assay technologies. These are critical tools for laboratories worldwide, instrumental in the isolation and preparation of nucleic acids, such as DNA and RNA. With these tools, researchers and clinicians can delve deeper into the molecular underpinnings of diseases, paving the way for breakthroughs in diagnostics and treatment. Qiagen’s financial engine is fueled by its diverse array of products and services, ranging from consumables like reagents and kits to sophisticated equipment for automating laboratory processes. Its diagnostic solutions are pivotal in areas like oncology, infectious diseases, and personalized medicine, enabling institutions to detect and analyze genetic information with precision. Additionally, Qiagen earns revenue by supporting pharmaceutical and biotech firms in their quest to discover and develop new drugs, ultimately contributing to safer, more effective treatments. The company also benefits from strategic collaborations and partnerships, continually expanding its influence and technological prowess. Through this multifaceted approach, Qiagen not only thrives in the competitive biotech landscape but also plays a critical role in transforming molecular data into actionable healthcare outcomes.
